Page 1 | Search Results | Blood Advances | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1 -mutant AML

Blood Adv (2024) 8 (18): 4845–4855.

https://doi.org/10.1182/bloodadvances.2024012858

Published: 2024

Includes: Supplemental data

Journal Articles

Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL

Blood Adv (2022) 6 (17): 4936–4948.

https://doi.org/10.1182/bloodadvances.2022007597

Published: 2022

Includes: Supplemental data

Journal Articles

Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide

Monzr M. Al Malki, Joycelynne Palmer, Ni-Chun Tsai, Sally Mokhtari, Susanta Hui, Weimin Tsai, Ibrahim Aldoss, Haris Ali, Ahmed Aribi, Thai Cao, Mathew Mei, Karamjeet S. Sandhu, Tanya Siddiqi, Stephen J. Forman, Ryotaro Nakamura, Guido Marcucci, Anthony Stein, Jeffrey Y. C. Wong, Joseph Rosenthal

Blood Adv (2022) 6 (14): 4098–4106.

https://doi.org/10.1182/bloodadvances.2022007264

Published: 2022

Includes: Supplemental data

Journal Articles

Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study

Haris Ali, Ni-Chun Tsai, Timothy Synold, Sally Mokhtari, Weimin Tsia, Joycelynne Palmer, Tracey Stiller, Monzr Al Malki, Ibrahim Aldoss, Amandeep Salhotra, Syed Rahmanuddin, Vinod Pullarkat, Ji-Lian Cai, Anthony Stein, Stephen J. Forman, Guido Marcucci, Matthew Mei, David S. Snyder, Ryotaro Nakamura

Blood Adv (2022) 6 (5): 1444–1453.

https://doi.org/10.1182/bloodadvances.2021005035

Published: 2022

Includes: Supplemental data

Journal Articles

Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)

Blood Adv (2021) 5 (13): 2775–2787.

https://doi.org/10.1182/bloodadvances.2021004233

Published: 2021

Includes: Supplemental data

Journal Articles

Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplant

Monzr M. Al Malki, Ni-Chun Tsai, Joycelynne Palmer, Sally Mokhtari, Weimin Tsai, Thai Cao, Haris Ali, Amandeep Salhotra, Shukaib Arslan, Ibrahim Aldoss, Nicole Karras, Chatchada Karanes, Jasmine Zain, Samer Khaled, Anthony Stein, David Snyder, Guido Marcucci, Stephen J. Forman, Ryotaro Nakamura

Blood Adv (2021) 5 (12): 2650–2659.

https://doi.org/10.1182/bloodadvances.2021004192

Published: 2021

Includes: Supplemental data

Journal Articles

Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)

Blood Adv (2021) 5 (10): 2481–2489.

https://doi.org/10.1182/bloodadvances.2020003605

Published: 2021

Includes: Supplemental data

Journal Articles

Identifying CD38 + cells in patients with multiple myeloma: first-in-human imaging using copper-64–labeled daratumumab

Blood Adv (2020) 4 (20): 5194–5202.

https://doi.org/10.1182/bloodadvances.2020002603

Published: 2020

Includes: Supplemental data

Journal Articles

Midostaurin in patients with acute myeloid leukemia and FLT3 -TKD mutations: a subanalysis from the RATIFY trial

Blood Adv (2020) 4 (19): 4945–4954.

https://doi.org/10.1182/bloodadvances.2020002904

Published: 2020

Includes: Supplemental data

Journal Articles

Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801

Guido Marcucci, Susan Geyer, Kristina Laumann, Weiqiang Zhao, Donna Bucci, Geoffrey L. Uy, William Blum, Ann-Kathrin Eisfeld, Timothy S. Pardee, Eunice S. Wang, Wendy Stock, Jonathan E. Kolitz, Jessica Kohlschmidt, Krzysztof Mrózek, Clara D. Bloomfield, Richard M. Stone, Richard A. Larson

Blood Adv (2020) 4 (4): 696–705.

https://doi.org/10.1182/bloodadvances.2019000492

Published: 2020

Journal Articles

Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents

Ibrahim Aldoss, Sanjeet Dadwal, Jianying Zhang, Bernard Tegtmeier, Matthew Mei, Shukaib Arslan, Monzr M. Al Malki, Amandeep Salhotra, Haris Ali, Ahmed Aribi, Karamjeet Sandhu, Samer Khaled, David Snyder, Ryotaro Nakamura, Anthony S. Stein, Stephen J. Forman, Guido Marcucci, Vinod Pullarkat

Blood Adv (2019) 3 (23): 4043–4049.

https://doi.org/10.1182/bloodadvances.2019000930

Published: 2019

Journal Articles

Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614)

Jun Yin, Betsy LaPlant, Geoffrey L. Uy, Guido Marcucci, William Blum, Richard A. Larson, Richard M. Stone, Sumithra J. Mandrekar

Blood Adv (2019) 3 (11): 1714–1721.

https://doi.org/10.1182/bloodadvances.2018026112

Published: 2019

Includes: Supplemental data

Journal Articles

Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting

Blood Adv (2019) 3 (7): 1027–1032.

https://doi.org/10.1182/bloodadvances.2018027227

Published: 2019

Includes: Supplemental data

Journal Articles

MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen

Blood Adv (2019) 3 (1): 83–95.

https://doi.org/10.1182/bloodadvances.2018026658

Published: 2019

Includes: Supplemental data

Journal Articles

Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)

Blood Adv (2018) 2 (24): 3608–3617.

https://doi.org/10.1182/bloodadvances.2018023689

Published: 2018

Includes: Supplemental data

Journal Articles

A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3 -mutated acute myeloid leukemia: CALGB 11001

Geoffrey L. Uy, Sumithra J. Mandrekar, Kristina Laumann, Guido Marcucci, Weiqiang Zhao, Mark J. Levis, Heidi D. Klepin, Maria R. Baer, Bayard L. Powell, Peter Westervelt, Daniel J. DeAngelo, Wendy Stock, Ben Sanford, William G. Blum, Clara D. Bloomfield, Richard M. Stone, Richard A. Larson

Blood Adv (2017) 1 (5): 331–340.

https://doi.org/10.1182/bloodadvances.2016003053

Published: 2017

NARROW

Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1 -mutant AML

Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL

Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide

Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study

Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)

Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplant

Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)

Identifying CD38 + cells in patients with multiple myeloma: first-in-human imaging using copper-64–labeled daratumumab

Midostaurin in patients with acute myeloid leukemia and FLT3 -TKD mutations: a subanalysis from the RATIFY trial

Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801

Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents

Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614)

Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting

MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen

Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)

A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3 -mutated acute myeloid leukemia: CALGB 11001

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only